The country’s drug evaluation agency registered a jump in new drug and clinical trial applications, signaling a robust pivot toward healthcare innovation
00:00/00:00
您的浏览器不支持 audio 标签。
Listen to this article
1x
China’s regulatory approvals for new pharmaceuticals surged to a five-year high in 2025, as government efforts to fast-track novel treatments sparked a record number of green lights for first-in-class innovative drugs.
Drugmakers guard IP more tightly amid China competition
Clinical Trials Day 2026: ‘Research Rising’ theme reflected in Q1 study growth - Pharmaceutical Technology
AstraZeneca picks up FDA approval for hypertension drug
FDA floats possible approach to repurpose approved drugs under new uses
White House adds 600 generic meds to TrumpRx purchasing portal
Post-Hoc: The next big pharma company will come from China
Regulatory round-up: A month of key FDA approvals for cancer drugs - Pharmaceutical Technology
